Composite remission rates including MH were significantly greater with combination therapy ( 52.3-56 .9 % ) vs. infliximab ( 25.6-32 .3 % ; P0 .015 for all comparisons except CRPnorm + MH , P = 0.017 ) and vs. azathioprine monotherapy ( 12.9-20 .4 % ; P0 .002 for all comparisons ) .